The board of directors of Mydecine Innovations Group Inc. MYCOF voted in favor of completing a reverse stock split. With this action, the company will consolidate all issued and outstanding shares on a base of 1-for-50.
According to Mydecine, the consolidation is expected to reduce the number of common shares from 268,515,954 to 5,370,319.
Although not yet approved by the NEO Exchange, the effective date for the consolidation and the announcement of the new CUSIP and ISIN numbers are expected to be completed within the next week.
Photo: Courtesy of Chris Liverani on Unsplash
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
